Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") (Nasdaq Stockholm: XBRANE) has entered into an agreement withAkademiska Hus for the lease of new premises on Campus Solna.- In
March 2021 , Xbrane will establish a new development lab for biosimilars with significantly expanded capacity compared to the current and will at the same time move its headquarter to Campus Solna. - From the second quarter of 2021 and onwards, Xbrane will further expand its portfolio and initiate development of additional biosimilar candidates on blockbuster biologics with patent expiration during this decade.
Xbrane has expanded significantly in recent years and successfully advanced its leading biosimilar candidate Xlucane (Lucentis® biosimilar) into phase III and entered into strategic partnerships with STADA, a European biosimilar specialist, and Bausch + Lomb, a leading global eye product and pharmaceutical company. In addition, Xbrane has three additional pre-clinical biosimilar candidates under development that address total originator sales of just under
To take the next step in the company's ambition to become a leading global biosimilar developer and broaden its biosimilar portfolio, the company has entered into an agreement with
“In order to fully leverage our platform technology and achieve our goal of becoming a leading global biosimilar developer, it is time for us to expand our capacity and broaden our portfolio. We have the technology and know-how and want to use it to develop more biosimilars on blockbuster biologics with patent expiration during this decade. The premises at Campus Solna suit us well for this purpose.”, Comments Martin Åmark, CEO.
© Modular Finance, source